Drug intelligence / Profile preview

TLC502

Development stage: Preclinical
Lead developer: Taiwan Liposome Company
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intraarticular

Overview

TLC502 is a small molecule drug candidate developed by Taiwan Liposome Company (TLC BioSciences) for the treatment of osteoarthritis, particularly knee osteoarthritis. It is formulated using a proprietary lipid-based delivery system and is designed to provide chondroprotection and stimulate chondrogenesis, potentially acting as a disease-modifying osteoarthritis drug (DMOAD). Preclinical studies have shown that TLC502 may slow or halt the progression of osteoarthritis by protecting cartilage and promoting new cartilage formation. The drug leverages advancements in biotechnology to target novel pathways involved in joint degeneration[1][2].

Beyond the preview

Go deeper on TLC502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLC502.

Explore the full profile